Literature DB >> 11856210

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics.

Caroline Rynn1, Mandy Wootton, Karen E. Bowker, H. Alan Holt, David S. Reeves.   

Abstract

OBJECTIVE: To study the interactions of colistin (MIC 2 mg/L) at concentrations of 0.5 and 5 mg/L with ceftazidime (1 and 75 mg/L, MIC 0.5 mg/L), aztreonam (1 and 30 mg/L, MIC 0.12 mg/L), meropenem (1 and 25 mg/L, MIC 0.03 mg/L), gentamicin (1 and 10 mg/L, MIC 2 mg/L), piperacillin (5 and 100 mg/L, MIC 4 mg/L) and ciprofloxacin (0.25 and 4 mg/L, MIC 1 mg/L) using a representative strain of Pseudomonas aeruginosa isolated from a cystic fibrosis patient.
METHODS: The method used was a bacterial time kill curve with single agents and combinations. Using inocula of 106 CFU/mL, multiple sampling was performed over 6 h and in triplicate. The AUBKC of the time versus viable count curve, with single agents and combinations of agents, was taken as the endpoint for comparison.
RESULTS: For colistin plus ceftazidime, colistin plus aztreonam, colistin plus meropenem and colistin plus ciprofloxacin, the pattern was for all the combinations (high or low concentrations) to produce smaller AUBKCs than single agents. In experiments using a bacteriostatic agent such as ceftazidime, the AUBKCs (log CFU/µL per h) for colistin 0.5 mg/L or 5 mg/L alone were 32.3±0.8 or 12.7±0.5, and for ceftazidime 1 mg/L or 75 mg/L alone they were 24.3±1.5 or 20.9±2.7. Combinations of colistin 0.5 mg/L plus either ceftazidime 1 mg/L or 75 mg/L produced AUBKCs of 23.8±1.8 or 16.1 mg/L. Combinations of colistin 5 mg/L plus ceftazidime 1 mg/L or 75 mg/L produced AUBKCs of 12.2±0.8 or 8.7±1.0. The AUBKCs for colistin 5 mg/L plus 75 mg/L are significantly smaller than those for the single agents, indicating synergy. In experiments using the bactericidal agent ciprofloxacin, the AUBKCs (log CFU/mL per h) for colistin 0.5 mg/L or 5 mg/L alone were 33.6±1.9 or 11.2±2.4, and for ciprofloxacin 0.25 mg/L or 4 mg/L alone they were 32.8±1.3 or 5.0±0.7. Combinations of colistin 0.5 mg/L plus either ciprofloxacin 0.25 mg/L or 4 mg/L produced AUBKCs of 32.2±0.9 or 4.3±1.4. Combinations of colistin 5 mg/L plus ciprofloxacin 0.25 mg/L or 4 mg/L produced AUBKCs of 10.7±1.5 or 4.2±0.6. Although combination AUBKCs were smaller than those for single agents, in no case did this reach statistical significance (p<0.05).
CONCLUSIONS: These studies indicate that addition of colistin to other antipseudomonal drugs tends to produce smaller AUBKCs and hence greater killing of Pseudomonas aeruginosa than monotherapy.

Entities:  

Year:  1999        PMID: 11856210     DOI: 10.1111/j.1469-0691.1999.tb00095.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  15 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.

Authors:  Phillip J Bergen; Alan Forrest; Jürgen B Bulitta; Brian T Tsuji; Hanna E Sidjabat; David L Paterson; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Authors:  Sofia K Kasiakou; Argyris Michalopoulos; Elpidoforos S Soteriades; George Samonis; George J Sermaides; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae.

Authors:  Mahableshwar Albur; Alan Noel; Karen Bowker; Alasdair MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

6.  The use of intravenous colistin among children in the United States: results from a multicenter, case series.

Authors:  Pranita D Tamma; Jason G Newland; Pia S Pannaraj; Talene A Metjian; Ritu Banerjee; Jeffrey S Gerber; Scott J Weissman; Susan E Beekmann; Philip M Polgreen; Adam L Hersh
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

7.  Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections.

Authors:  M Montero; J P Horcajada; L Sorlí; F Alvarez-Lerma; S Grau; M Riu; M Sala; H Knobel
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

Review 8.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

9.  Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Deana M Sabuda; Kevin Laupland; Johann Pitout; Bruce Dalton; Harvey Rabin; Thomas Louie; John Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

10.  Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.

Authors:  Nikolaos Markou; Haralampos Apostolakos; Christiana Koumoudiou; Maria Athanasiou; Alexandra Koutsoukou; Ioannis Alamanos; Leonidas Gregorakos
Journal:  Crit Care       Date:  2003-07-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.